Navigation Links
Northwest Biotherapeutics Announces Change and Expansion of Management Team
Date:6/8/2011

S and internationally.

Dr. Maida has been responsible for negotiating partnering and licensing transactions with many premier pharmaceutical companies and academic centers of excellence, including, among others, Eli Lilly, Novartis, RCT Corporation, Astra Zeneca, Pfizer, Bristol Myers Squibb, MD Anderson, Yale University, Stanford University, University of California San Francisco and Davis, and the Wistar Institute.  Dr. Maida's already strong scientific expertise was further strengthened as he recently completed and in 2010 received a PhD in Tumor Immunology.  On the financial front, Dr. Maida has served for years as a key adviser to many large institutional investors for their oncology investments.  Dr. Maida serves on several boards in the oncology field, including Spectrum Pharmaceuticals and others.  Earlier in his career, Dr. Maida served for a number of years as the Chief Financial Officer of a large public company's subsidiary and Senior Financial Controller of a $1.7 billion division of that company (Lockheed).

Ms. Powers has served as Chairman of NWBT for the last 4 years, and brings more than 25 years' experience in corporate transactions and operations, including more than a decade specializing in building biotech companies through Toucan Capital.  Ms. Powers is particularly well known for her experience in building biotech companies that are developing cell therapies, including both immune cell therapies (such as NWBT's DCVax®) and adult stem cell therapies.  Such products -- consisting of living human cells -- require fundamentally different manufacturing, storage, distribution and handling than do pharmaceutical drugs ("pills in bottles").  Such living cell products also involve different clinical and regulatory requirements, and different business and cost/pricing models, than traditional drugs.  The cell therapy companies which Ms. Powers has been involved in building over the last decade,
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Northwestern chemists take gold, mass-produce Beijing Olympic logo
2. Northwest Secures US$1.0 Million Debt Financing
3. Northwest Secures US$1.65 Million Debt Financing
4. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
5. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
6. Northwest Biotherapeutics Secures $700,000 Equity Financing
7. Sirius Genomics to Present at Invest Northwest Conference
8. Oncothyreon to present at Invest Northwest 2009
9. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
10. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
11. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... Md. , Aug. 26, 2015 Intrexon ... biology, announced today the closing of its previously announced ... full by the underwriters of their option to purchase ... public offering price of $41.00 per share.  The exercise ... shares of common stock sold by Intrexon to 5,609,756 ...
(Date:8/26/2015)... -- After litigating and negotiating patent infringement claims ... United States patent RE43,651 (the ,651 ... the United States without any admission or concession ... As a result of the parties, settlement, the US District ... dismissed the case without prejudice. Under the ...
(Date:8/26/2015)... ... , ... The 2015 Epigenomics & Metabolomics Meeting in Boston was ... to share the first report on progress with its crowdsourcing campaign designed to ... stem cells. , With a name like “H2A.Z asymmetry,” the new biomarker would require ...
(Date:8/25/2015)... ... August 25, 2015 , ... ... facility in Knapp, Wis. The company has added a AS16 Sharples centrifuge to ... data collection during bacterial or fungal fermentation process development. , The new ...
Breaking Biology Technology:Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4P2i Settles United States Litigation 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4New centrifuge and fermentor expand product development capacity at Vets Plus 2
... ChemDiv, Inc., a leading,chemistry-driven global contract research ... into a discovery collaboration with Achaogen, Inc.,South ... medicinal and synthetic,chemistry, ChemDiv will support Achaogen ... terms of the collaboration were,not disclosed., ...
... at year end; no equity financings expected in 2008, ... to continue in,2008; latest data for all programs to ... - Expansion of research and development investment in pharmacological, ... in 2008, CRANBURY, N.J., Jan. 29 Amicus ...
... Jan. 29 Surface Logix today announced ... trial of SLx-4090 in,dyslipidemia (high cholesterol and ... placebo-controlled Phase 2a study in 24,patients with ... in postprandial triglycerides and LDL-cholesterol,and was well ...
Cached Biology Technology:ChemDiv and Achaogen Enter Into a Discovery Collaboration 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 4Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 5Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 6Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 7Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 8Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 9Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 10Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 11Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 12Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 13Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 14Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial 2Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial 3Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial 4
(Date:8/5/2015)... August 5, 2015 According to ... Management Market by Software, Services, Vertical (BFSI, Airport, IT & ... - Global Forecast to 2020", published by MarketsandMarkets, defines ... globally into various segments. The global PIAM Market is ... $546.2 Million by 2019, at a CAGR of 14.9 ...
(Date:8/5/2015)... VIEW, Calif. , Aug. 5, 2015 ... exhibits continuous growth in applications, penetration into newer sectors, ... after year. The global biosensors space has seen the ... exited the market so far. (Photo - ... Frost & Sullivan, Analysis of the Global Biosensors ...
(Date:8/4/2015)... ) today reported financial and operating results for the second quarter ... quarter contract revenue of $ 85.2 million, a ... of 26 % , Second quarter adjusted ... royalties in the current quarter , Operating cash ... to present another strong financial quarter, with all our divisions achieving ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... to findings by UT Southwestern Medical Center researchers, individuals ... clots, or thrombosis, might someday receive therapy to prevent ... in a future issue of The Journal of ... underlying antiphospholipid syndrome (APS). "Patients with APS ...
... have recorded stunning images of the UK,s winter landscape ... have been observing the icy blast in the UK ... scientists have used two instruments, MERIS and AATSR, which ... observations on November 29th and December 1st. ...
... alteration of a single gene could cause some male ... improve diagnosis and clinical management of patients with disorders ... testis or ovary does not develop properly in the ... An international team including researchers from the ...
Cached Biology News:UT Southwestern researchers uncover culprits in life-threatening clotting disorder 2Snow from space: University of Leicester releases satellite images of snow-bound UK 2